Description
Latin name BrdTrd
Release form
Eye drops 0.25%.
Packing
5 ml – plastic dropper bottle Drop Tainer (1) with a dispenser – packs of cardboard.
Pharmacological action
Anti-glaucoma drug. Selective beta1-blocker without internal sympathomimetic activity. It does not have a membrane stabilizing (local anesthetic) effect.
Anti-glaucoma drug. Selective beta1-blocker without internal sympathomimetic activity. It does not have a membrane stabilizing (local anesthetic) effect.
Topical application of betaxolol reduces intraocular pressure due to a decrease in the production of intraocular fluid.
The onset of the hypotensive effect is observed 30 minutes after instillation, the maximum effect develops after 2 hours. After a single instillation, the effect on ophthalmotonus persists for 12 hours.
Betaxolol (compared with other beta-blockers) does not cause a decrease in blood flow in the optic nerve.
Betoptik C does not cause myosis, spasm of accommodation, hemeralopia, the effect of the veil in front of the eyes (unlike myotics).
Pharmacokinetics
With topical administration of the drug, systemic absorption of betaxolol hydrochloride is possible.
Indications
The drug is used to reduce intraocular pressure as a monotherapy or in combination with other drugs for: Open-angle glaucoma.
Ocular hypertension.
Contraindications
Sinus bradycardia.
AV block II and III degree.
Cardiogenic shock.
Severe heart failure.
Hypersensitivity to the drug.
Caution: the drug should be prescribed for diabetes, pheochromocytoma, Raynaud’s syndrome.
Use during pregnancy and lactation
There is no sufficient experience with the use of Betoptik C during pregnancy and lactation. The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or child.
Composition
1 ml eye drops contains:
Active substances: betaxolol hydrochloride – 2.8 mg, which corresponds to a content of betaxolol – 2.5 mg.
Excipients: benzalkonium chloride, mannitol, carbomer 974P, polystyrenesulfonic acid, boric acid, disodium edetate, N-lauroyl sarcosine, hydrochloric acid and / or sodium hydroxide solution (to maintain pH), purified water.
Dosage and administration
The drug is instilled in the conjunctival sac, 1-2 drops 2 times / day.
In some patients, stabilization of intraocular pressure occurs within a few weeks, therefore it is recommended to control intraocular pressure during the first month of treatment.
With insufficient clinical efficacy of monotherapy, combination therapy should be prescribed.
Shake before use.
Side effects
From the side of the organ of vision: often – short-term discomfort in the eyes after instillation in some cases – blurred vision, acne keratitis, decreased sensitivity of the cornea, foreign body sensation in the eye, lacrimation, photophobia, itching, dry eyes, redness of the eyes, anisocoria, inflammation, pain, decreased visual acuity.
From the side of the central nervous system: insomnia, depressive neurosis.
Drug Interaction
Concurrent use of Betoptik C and beta blockers for intake increases the risk of side effects (such as local, and systemic ones) due to the additive effect (therefore, patients receiving this combination of drugs should be under medical supervision).
When using Betoptic C in combination with drugs that deplete catecholamines (such as reserpine), blood pressure and bradycardia may be reduced.
Overdose
In case of contact with excess drug, rinse eyes with warm water.
Storage conditions
Store upright, out of the reach of children, at a temperature of 8 ° to 30 ° C.
Expiration
2 years. After opening the vial, the drug should be used within 1 month.
Deystvuyuschee substances
Betaxolol
dosage form
dosage form
eye drops
Alcon, USA
